Is there human data for these compounds?

Yes. Two 2006 studies in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 in healthy adults, which is more than most compounds in this library have.

Are there ongoing trials?

None currently established, unlike BPC-157 which has a Phase 2 recruiting.

What should I search besides the product names?

GRF(1-29) and sermorelin for the GHRH-analogue context, and NNC 26-0161 for ipamorelin's development records.

CJC-1295 and Ipamorelin in the Literature

The short answer

The core literature is small and unusually clinical for this field: two 2006 human studies in the Journal of Clinical Endocrinology and Metabolism on CJC-1295, and Raun's 1998 paper establishing ipamorelin's selectivity. There is comparatively little beyond them.

Key facts

Teichman 2006: CJC-1295 PK/PD in healthy adults
Ionescu & Frohman 2006: Pulsatility under continuous stimulation
Raun 1998: Ipamorelin selectivity
Human data: Present, unlike most of this library
Registered trials: None currently established
Search terms: Also NNC 26-0161, GRF(1-29)

A small literature with an unusual composition

Most research peptides have a large rodent literature and no human data. This pair has the opposite profile: a modest number of papers, two of which are controlled human studies in a mainstream endocrinology journal. Volume is low; quality of the core references is comparatively high.

The three papers that matter

Teichman and colleagues, JCEM 2006, on prolonged GH and IGF-I stimulation by CJC-1295 with DAC in healthy adults. Ionescu and Frohman, JCEM 2006, on whether pulsatile GH secretion survives continuous stimulation. Raun and colleagues, European Journal of Endocrinology 1998, establishing ipamorelin as the first selective growth hormone secretagogue. Nearly everything else cites one of these.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

What is absent

Registered interventional trials currently under way, unlike BPC-157, which has a Phase 2 recruiting. Long-term data of any kind. And studies of the combination with the single-agent arms that would be needed to say anything about additivity. The gaps are specific rather than general.

Searching it

CJC-1295 finds the compound directly. GRF(1-29) and sermorelin surface the wider GHRH-analogue literature that gives context. NNC 26-0161 finds ipamorelin's development-era records. Searching only the product names returns a mix of commercial content and the handful of primary papers.

How this category compares within the library

Better human pharmacokinetic data than GHK-Cu, TB-500, DSIP, Semax or Selank. Less clinical development than BPC-157, which has a Phase 2 recruiting. And far less than the incretins, which have outcome trials with tens of thousands of participants. A useful middle position, and an honest one to state.

Frequently asked questions

Is there human data for these compounds?: Yes. Two 2006 studies in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 in healthy adults, which is more than most compounds in this library have.
Are there ongoing trials?: None currently established, unlike BPC-157 which has a Phase 2 recruiting.
What should I search besides the product names?: GRF(1-29) and sermorelin for the GHRH-analogue context, and NNC 26-0161 for ipamorelin's development records.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
▸Ghrelin-receptor binding assays for Ipamorelin analogue development
▸Analytical HPLC method development for lipidated GHRH analogues
▸Stability testing under refrigerated storage

Handling checklist

✓Store lyophilised at −20 °C long-term
✓Reconstitute in bacteriostatic water; both peptides dissolve readily
✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

What the Published Literature Contains